Gundu HR Rao*

Emeritus Professor, Laboratory Medicine and Pathology, Director, Thrombosis Research, Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota, USA

*Corresponding Author: Emeritus Professor, Laboratory Medicine and Pathology, Director, Thrombosis Research, Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota, USA

Received: May 10, 2021; Published: May 25, 2021

Abstract

  Desperate times needs desperate measures. According to health experts in India, the country recorded the highest COVID-related deaths per day exceeding 4500 this week. India the largest democracy, managed the first COVID surge very well by initiating a complete lockdown even though the number of COVID infected individuals were not very large. The leaders declared that they had won the war against the killer virus. However, the second wave of the virus spread like a forest fire without giving any time to get prepared for this tsunami, exposing the vulnerabilities of an inadequate healthcare system. This unprecedented pandemic has created a nightmare for public health workers, critical care workers, clinicians, nurses, medical supply chain and services. The country has realized the magnitude of the problem and has not found a way to get out of this health care crisis. It is high time that the country should put together an ‘expert committee’ and develop a robust prevention and management strategy. In the absence of such a task force the public health issues are left to the officials of various States and Districts. The leadership went from ‘it is not a problem anymore’ to ‘it has gone too far to do anything.’ India cannot afford another lockdown as the low-income and resource poor individuals will suffer. They can follow limited lockdown and initiate strict public health best practices immediately. They also should accelerate vaccine production and vaccination of all eligible adults. What is certain is that India, will vaccinate far more people than any other nation by the end of the year. India will come out of this crisis with an improved healthcare infrastructure.

Keywords: Coronavirus; COVID-19; Killer Virus; Call for Action

References

1. Rao GHR. “Coronavirus Disease Prevention: Opportunities and Challenges”. Acta Scientific Pharmacology 5 (2021): 19-22.
2. Rao GHR. “COVID-19 and Cardiometabolic Diseases: Guest Editorial”. EC Cardiology6 (2020): 8-12.
3. Rao GHR. “Coronavirus Disease (COVID-19) and Acute Vascular Events”. Clinical and Applied Thrombosis/Hemostasis 26 (2020).
4. Rao GHR. “Coronavirus Disease (COVID-19), Comorbidities and Clinical Manifestations”. EC Diabetes and Metabolic Research 6 (2020): 27-33.
5. Rao GHR. “Coronavirus (COVID-19), Comorbidities and Acute Vascular Events”. EC Clinical Case Reports6 (2020): 87-91.
6. Rao GHR. “Pharmacological Approaches for Infection Prevention: Old and the New”. Acta Scientific Pharmacology8 (2020): 33-37.
7. Rao GHR. “Coronavirus Disease (COVID-19): A Disease of the Vascular Endothelium”. Series of Cardiology Research1 (2020): 521-528.
8. Rao GHR. “Pharmacology: Clinical Applications and Therapeutics”. Acta Scientific Pharmacology 6 (2020): 5-7.
9. Rao GHR. “Covid-19: Anxiety, Stress, Fear and Heart Health”. EC Cardiology9 (2020).
10. Rao GHR. “Covid-19: A Public Health Perspective”. Journal of Medicine and Healthcare 4 (2020): 1-7.
11. Rao GHR. “Coronavirus Transmission, Vascular Dysfunction, and Pathology”. Journal of Cardiology Research Reviews and Reports 3 (2020): 1-4.
12. Rao GHR. “Excess weight, Obesity, Diabetes and Coronavirus Disease”. Archives of Diabetes and Obesity 1 (2020).
13. Rao GHR. “SARS-CoV-2 biochemistry, Transmission, Clinical Manifestations, and Prevention”. International Journal of Biomedicine 4 (2020): 303-311.
14. Rao GHR. “Clinical manifestation of coronavirus disease as it relates to cardiovascular health”. Frontiers in Cardiovascular Medicine 1 (2020): IDFJCCM-20-103.
15. Rao GHR. “Inflammation: Need for the development of Novel Immunomodulators”. Acta Scientific Pharmacology1 (2021): 05-09.
16. Rao GHR. “Syndemic of Coronavirus Disease and Metabolic Diseases; A global Perspective”. 6.4 (2021): 28-32.
17. Priyanka Pilla. “There are so many hurdles.' Indian scientists plead with the government to unlock COVID-19 data”. Asia/Pacific, Health, Coronavirus (2021).
18. Jay Cohen. “Will India's devastating COVID-19 surge provides data that clear up its death 'paradox'?” Asia/Pacific, Coronavirus (2021).
19. Rabesandratana T. “After coronavirus vaccine failures, France laments the state of its biomedical R& D”. Europe, Scientific Community (2021).
20. Arora P., et al. “Prediction and analysis of COVID-19 positive cases using deep learning models: A descriptive case study in India”. Chaos, Solitons and Fractals (2020): 139.
21. “EDITORIAL: India’s Covid Emergency”. The Lancet10286 (2021): P1683.

Citation

Citation: Gundu HR Rao. “The Tsunami of a Killer Virus (SARS-CoV2) Ravages India: Call for Action. Viewpoint (Short Communication)".Acta Scientific Pharmacology 2.6 (2020): 32-37.

Copyright

Copyright: © 2021 Gundu HR Rao. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.